Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Health Minister to Make Direct Request to 24 Makers for Supply Ramp-Up
November 7, 2023
- Japan PM Advisor Pushes Rethink of LLP Coverage to Reward Innovation, Pricing Debate without Taboos
November 6, 2023
- Japan OKs New Economic Package; Startup, Pharma Promotion Embraced
November 6, 2023
- FPMAJ Renews Call for Premium for Drugs Launched in Japan without Delay: LDP Confab
November 6, 2023
- Reward Innovation by Revisiting LLP Copay, Cut Doctor Fees: MOF
November 2, 2023
- Japan PM Pins Hope for Leadership of Kamoshita as Drug Policy Advisor
November 2, 2023
- MHLW to Consider Investigation on OTC Drug Abuse: Minister
November 2, 2023
- Organization to Push Drug Discovery Is One Option: Health Minister
November 1, 2023
- Basic Dementia Law Set to Take Effect on January 1: MHLW
November 1, 2023
- Japan Economic Package to Call for Boosting Innovation for Next-Gen Biologics
November 1, 2023
- Cases of Unintentional Xocova Use in Pregnant Women Total 32: MHLW
October 31, 2023
- AMED, Europe’s HERA to Cooperate in Medical Countermeasures
October 31, 2023
- PMDA Investigating Safety Risks of Eliquis, Other Anticoagulants for Acute Kidney Injury
October 30, 2023
- No Objections to Reflecting Company Indices for Generic Supplies in Pricing: Chuikyo
October 30, 2023
- Medical, Long-Term Care Data Linkage Holds Key to CEA: Leqembi Debate
October 30, 2023
- Panel OKs Xarelto’s Label Expansion for Post-Fontan Heart Failure Patients
October 30, 2023
- Lawmakers Demand NIP Coverage for Male Use of 4-Valent HPV Vaccine
October 26, 2023
- Japan’s Healthcare Spending Hits 45 Trillion Yen in FY2021
October 26, 2023
- Japan to Push 2024 Reform Debate by Using Price “Maintenance” and “Raise” Rules: PM
October 26, 2023
- Japan to Deliberate Pricing Measures for Stable Drug Supplies: Draft Economic Package
October 25, 2023
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…